Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer
- PMID: 2578313
Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer
Abstract
To evaluate the prognostic value of prostate-specific antigen (PA) for detection of tumor growth after definitive therapy, 602 sera from 70 patients with stages B2 to D1 prostate cancer (26 of whom recurred) were analyzed in a blind study. Using Cox's proportional-hazards model, a highly significant association was found between serially measured PA and disease-free survival time (p = 0.0002). A positive predictive value of 100% was found for some markedly elevated PA levels and confirmed recurrence of disease. In fact, this study suggested that once a PA level of 88 ng/ml was reached, there was an average time of less than 2 months before a recurrence was clinically confirmed. Tumor growth in patients who recurred was indicated by a PA elevation before recurrence in 92% (24 of 26) as opposed to 20% (9 of 44) in disease-free patients. Additionally, in these 24 of 26 patients, levels of PA were elevated 12 months (mean lead time) before a confirmed disease recurrence. In patients who were still disease free, serial PA appeared to increase concurrently with putative tumor growth as shown by the initial surgical stage. Generally, the greater the PA level the more advanced was the stage of disease (B2 to D1). These data suggest that PA may be a useful adjuvant marker for monitoring tumor growth in patients with regionally confined prostate cancer.
Similar articles
-
Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.J Natl Cancer Inst. 1986 Feb;76(2):179-85. J Natl Cancer Inst. 1986. PMID: 2418245 Clinical Trial.
-
Use of human prostate-specific antigen in monitoring prostate cancer.Cancer Res. 1981 Oct;41(10):3874-6. Cancer Res. 1981. PMID: 7284995
-
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.Urology. 1996 Aug;48(2):249-60. doi: 10.1016/S0090-4295(96)00167-7. Urology. 1996. PMID: 8753737
-
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.J Urol. 2005 Sep;174(3):903-7. doi: 10.1097/01.ju.0000169475.00949.78. J Urol. 2005. PMID: 16093984
-
Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.J Urol. 2005 Dec;174(6):2181-5. doi: 10.1097/01.ju.0000181215.41607.c3. J Urol. 2005. PMID: 16280760
Cited by
-
Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.PLoS One. 2021 May 3;16(5):e0249709. doi: 10.1371/journal.pone.0249709. eCollection 2021. PLoS One. 2021. PMID: 33939714 Free PMC article.
-
Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities.Biology (Basel). 2021 Apr 5;10(4):297. doi: 10.3390/biology10040297. Biology (Basel). 2021. PMID: 33916347 Free PMC article.
-
A stochastic model for PSA levels: behavior of solutions and population statistics.J Math Biol. 2006 Sep;53(3):437-63. doi: 10.1007/s00285-006-0016-z. Epub 2006 Jul 11. J Math Biol. 2006. PMID: 16832692
-
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.Am J Pathol. 2002 Dec;161(6):2053-63. doi: 10.1016/S0002-9440(10)64484-7. Am J Pathol. 2002. PMID: 12466122 Free PMC article.
-
Performance evaluation of a new chemiluminescent assay for prostate specific antigen.J Clin Lab Anal. 2000;14(4):164-8. doi: 10.1002/1098-2825(2000)14:4<164::aid-jcla5>3.0.co;2-m. J Clin Lab Anal. 2000. PMID: 10906769 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical